{"title_page": "RTI-229", "text_new": "{{Drugbox\n| verifiedrevid = 451551869\n| IUPAC_name = [(1''R'',2''S'',3''S'',5''S'')-3-(4-Iodophenyl)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl]-pyrrolidin-1-ylmethanone\n| image = Phenyltropane 28a.svg\n| width = 200\n\n<!--Clinical data-->\n| tradename =  \n| legal_status = Legal\n\n<!--Identifiers-->\n| CAS_number_Ref = {{cascite|correct|??}}\n| CAS_number = 160948-17-4\n| PubChem = 9910220\n\n<!--Chemical data-->\n| C=19 | H=25 | I=1 | N=2 | O=1 \n| smiles = CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)I)C(=O)N4CCCC4\n}}\n\n'''RTI-229''', also known as '''(\u2013)-3\u03b2-(4-iodophenyl)tropane-2\u03b2-pyrrolidine carboxamide''' and '''RTI-''4229''-229''', is a potent and long-lasting [[stimulant]] drug which was developed in the 1990s as part of a large group of related analogues from the [[phenyltropane]] family. With the combination of two potent [[dopamine transporter]] (DAT) binding motifs attached to the [[tropane]] ring, the p-[[iodine|iodo]][[phenyl]] group at the 3\u03b2-position and a [[pyrrolidine]] [[carboxamide]] at 2\u03b2, RTI-229 has extremely high selectivity for the dopamine transporter (2600x and 4600x selective over [[noradrenaline transporter|NET]] and [[serotonin transporter|5-HTT]] respectively) and is one of the most DAT-selective compounds in the RTI series.<ref>{{cite journal | vauthors = Carroll FI, Kotian P, Dehghani A, Gray JL, Kuzemko MA, Parham KA, Abraham P, Lewin AH, Boja JW, Kuhar MJ | display-authors = 6 | title = Cocaine and 3 beta-(4'-substituted phenyl)tropane-2 beta-carboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter | journal = Journal of Medicinal Chemistry | volume = 38 | issue = 2 | pages = 379\u201388 | date = January 1995 | pmid = 7830281 | doi = 10.1021/jm00002a020 }}</ref><ref name=\"pmid11749256\">{{cite journal | vauthors = Singh S | title = Chemistry, design, and structure-activity relationship of cocaine antagonists | journal = Chemical Reviews | volume = 100 | issue = 3 | pages = 925\u20131024 | date = March 2000 | pmid = 11749256 | doi = 10.1021/cr9700538 }}</ref>\n\n==Uses==\nRTI-229 is mainly used in scientific research into the [[dopamine]] reuptake transporter, with its extremely high DAT selectivity making it useful for distinguishing between DAT and NET binding sites in the brain to an even greater extent than related compounds such as [[RTI-121]].<ref>{{cite journal | vauthors = Zhong D, Kotian P, Wyrick CD, Seltzman HH, Kepler JA, Kuhar MJ, Boja JW, Carroll FI | date = Mar 1999 | title = Synthesis of 3\u03b2-(4-[<sup>125</sup>I]iodophenyl)tropane-2\u03b2-pyrrolidine carboxamide ([<sup>125</sup>I]RTI-229) | url = | journal = Journal of Labelled Compounds and Radiopharmaceuticals | volume = 42 | issue = 3| pages = 281\u2013286 | doi=10.1002/(sici)1099-1344(199903)42:3<281::aid-jlcr188>3.3.co;2-o}}</ref>\n\n==Legal Status==\nRTI-229 is legal throughout the world as of 2010. Some jurisdictions such as the United States, Australia and New Zealand might however consider RTI-229 to be a [[Federal Analog Act|controlled substance analogue]] of cocaine on the grounds of its related chemical structure.\n\n== See also ==\n* [[RTI-55]]\n* [[List of Phenyltropanes]]\n\n== References ==\n{{Reflist}}\n\n{{Stimulants}}\n{{Monoamine reuptake inhibitors}}\n{{Phenyltropanes}}\n{{Use dmy dates|date=April 2020}}\n\n{{Authority control}}\n\n{{DEFAULTSORT:Rti-229}}\n[[Category:Carboxamides]]\n[[Category:Pyrrolidines]]\n[[Category:Iodoarenes]]\n[[Category:Tropanes]]\n[[Category:RTI compounds]]\n[[Category:Dopamine reuptake inhibitors]]\n[[Category:Stimulants]]\n[[Category:Sympathomimetic amines]]\n[[Category:Medical imaging]]\n[[Category:Neuroimaging]]\n", "text_old": "{{Drugbox\n| verifiedrevid = 451551869\n| IUPAC_name = [(1''R'',2''S'',3''S'',5''S'')-3-(4-Iodophenyl)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl]-pyrrolidin-1-ylmethanone\n| image = Phenyltropane 28a.svg\n| width = 200\n\n<!--Clinical data-->\n| tradename =  \n| legal_status = Legal\n\n<!--Identifiers-->\n| CAS_number_Ref = {{cascite|correct|??}}\n| CAS_number = 160948-17-4\n| PubChem = 9910220\n\n<!--Chemical data-->\n| C=19 | H=25 | I=1 | N=2 | O=1 \n| smiles = CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)I)C(=O)N4CCCC4\n}}\n\n'''RTI-229''', also known as '''(\u2013)-3\u03b2-(4-iodophenyl)tropane-2\u03b2-pyrrolidine carboxamide''' and '''RTI-''4229''-229''', is a potent and long-lasting [[stimulant]] drug which was developed in the 1990s as part of a large group of related analogues from the [[phenyltropane]] family. With the combination of two potent [[dopamine transporter]] (DAT) binding motifs attached to the [[tropane]] ring, the p-[[iodine|iodo]][[phenyl]] group at the 3\u03b2-position and a [[pyrrolidine]] [[carboxamide]] at 2\u03b2, RTI-229 has extremely high selectivity for the dopamine transporter (2600x and 4600x selective over [[noradrenaline transporter|NET]] and [[serotonin transporter|5-HTT]] respectively) and is one of the most DAT-selective compounds in the RTI series.<ref>{{cite journal | vauthors = Carroll FI, Kotian P, Dehghani A, Gray JL, Kuzemko MA, Parham KA, Abraham P, Lewin AH, Boja JW, Kuhar MJ | display-authors = 6 | title = Cocaine and 3 beta-(4'-substituted phenyl)tropane-2 beta-carboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter | journal = Journal of Medicinal Chemistry | volume = 38 | issue = 2 | pages = 379\u201388 | date = January 1995 | pmid = 7830281 | doi = 10.1021/jm00002a020 }}</ref><ref name=\"pmid11749256\">{{cite journal | vauthors = Singh S | title = Chemistry, design, and structure-activity relationship of cocaine antagonists | journal = Chemical Reviews | volume = 100 | issue = 3 | pages = 925\u20131024 | date = March 2000 | pmid = 11749256 | doi = 10.1021/cr9700538 }}</ref>\n\n==Uses==\nRTI-229 is mainly used in scientific research into the [[dopamine]] reuptake transporter, with its extremely high DAT selectivity making it useful for distinguishing between DAT and NET binding sites in the brain to an even greater extent than related compounds such as [[RTI-121]].<ref>{{cite journal | vauthors = Zhong D, Kotian P, Wyrick CD, Seltzman HH, Kepler JA, Kuhar MJ, Boja JW, Carroll FI | date = Mar 1999 | title = Synthesis of 3\u03b2-(4-[<sup>125</sup>I]iodophenyl)tropane-2\u03b2-pyrrolidine carboxamide ([<sup>125</sup>I]RTI-229) | url = | journal = Journal of Labelled Compounds and Radiopharmaceuticals | volume = 42 | issue = 3| pages = 281\u2013286 | doi=10.1002/(sici)1099-1344(199903)42:3<281::aid-jlcr188>3.3.co;2-o}}</ref>\n\n==Legal Status==\nRTI-229 is legal throughout the world as of 2010. Some jurisdictions such as the United States, Australia and New Zealand might however consider RTI-229 to be a [[Federal Analog Act|controlled substance analogue]] of cocaine on the grounds of its related chemical structure.\n\n== See also ==\n* [[RTI-55]]\n* [[List of Phenyltropanes]]\n\n== References ==\n{{Reflist}}\n\n{{Stimulants}}\n{{Monoamine reuptake inhibitors}}\n{{Phenyltropanes}}\n{{Use dmy dates|date=September 2010}}\n\n{{DEFAULTSORT:Rti-229}}\n[[Category:Carboxamides]]\n[[Category:Pyrrolidines]]\n[[Category:Iodoarenes]]\n[[Category:Tropanes]]\n[[Category:RTI compounds]]\n[[Category:Dopamine reuptake inhibitors]]\n[[Category:Stimulants]]\n[[Category:Sympathomimetic amines]]\n[[Category:Medical imaging]]\n[[Category:Neuroimaging]]\n", "name_user": "Rich Farmbrough", "label": "safe", "comment": "\u2192\u200eReferences:Update date format tag", "url_page": "//en.wikipedia.org/wiki/RTI-229"}
